Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 11/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.51 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29367448 | 1.00 | CASP1 (0.59) | CASP1CAPN1CTSBCASP8CCR1 | |
| SCHEMBL3056806 | 1.00 | CASP1 (0.59) | CASP1CAPN1CTSBCASP8CCR1 | |
| SCHEMBL23234581 | 0.87 | CTSB (0.58) | CAPN1CTSB | |
| SCHEMBL28490124 | 0.83 | CASP1 (0.56) | CASP1CASP8CCR1PIN1 | |
| SCHEMBL7402876 | 0.83 | CASP1 (0.61) | CASP1CAPN1CTSBCASP8 | |
| SCHEMBL23235027 | 0.82 | CTSB (0.53) | CAPN1CTSB | |
| SCHEMBL20204722 | 0.81 | CTSB (0.62) | CAPN1CTSB | |
| SCHEMBL3907752 | 0.80 | CAPN1 (0.49) | CAPN1CTSB | |
| SCHEMBL7789989 | 0.80 | NR1H4 (0.58) | CAPN1PIN1 | |
| SCHEMBL7789992 | 0.80 | NR1H4 (0.58) | CAPN1PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102538-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE PRESENILIN FUNCTION AND GAMMA-SECRETASE ACTIVITY | AMICUS THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102538-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE PRESENILIN FUNCTION AND GAMMA-SECRETASE ACTIVITY | PSEN1, PSEN2, APP | CASP1 2265/4885CAPN1 137/4885CTSB 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.